Folic acid (FA) supplementation is recommended periconceptionally for the prevention of neural tube defects. Limited data are available on the folate status of New Zealand (NZ) pregnant women and its association with FA supplementation intake. Objectives of this study were to examine the relationship between plasma folate (PF) concentrations and reported FA supplement use at 15±1 weeks’ gestation, and to explore sociodemographic and lifestyle factors associated with PF. We used data and blood samples from NZ participants of the Screening for Pregnancy Endpoints (SCOPE) international pregnancy cohort study. Healthy nulliparous women with singleton pregnancy (n = 1921) were interviewed and blood samples collected. PF was analysed via microbiological assay. Seventy-three percent of participants reported taking an FA supplement at 15±1 weeks’ gestation - of these, 79% were taking FA as part of or alongside a multivitamin supplement. Fifty-six percent of FA supplement users reported consuming a daily dose of ≥800µg; 39% reported taking less than 400µg/day. Mean (±SE) PF was significantly higher in women reporting FAS (54.6 ±1.5nmol/L) vs no FAS (35.1 ±1.6 nmol/L) (p<0.0001). Reported daily FA supplement dose and PF were significantly positively correlated (r=0.41; p<0.05). Younger maternal age, Pacific and Māori ethnicity and obesity were negatively associated with PF levels; vegetarianism was positively associated with PF. Reported FA supplement dose was significantly associated with PF after adjustment for sociodemographic, lifestyle confounders and multivitamin intake. The relationship observed between FA supplement intake and PF demonstrates that self-reported intake is a reliable proxy for FA supplement use in this study population.